Probably in the near future, a negative hyper-selection of MSS/pMMR mCRC based on molecular profile other than RAS and BRAF genes could help further refine elderly patients’ treatment on top of primary tumor location, expanding the administration of anti-EGFR to susceptible right-sided mCRC patients [78,79]. The gene discussed is EGFR; the disease is neoplasm.